Chardan Capital Maintains Buy on Silence Therapeutics, Maintains $42 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Keay Nakae maintains a Buy rating on Silence Therapeutics (NASDAQ:SLN) with a $42 price target.
May 17, 2024 | 12:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Chardan Capital analyst Keay Nakae maintains a Buy rating on Silence Therapeutics (NASDAQ:SLN) with a $42 price target.
The reaffirmation of a Buy rating and a $42 price target by Chardan Capital is likely to positively impact investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100